AmpliPhi makes Philip Young CEO
This article was originally published in Scrip
Executive Summary
AmpliPhi Biosciences, a developer of bacteriophage-based antibacterial therapies, has appointed Philip Young president and CEO. Mr Young was formerly president and CEO of Osteologix, and is still on its board of directors. Edward Cappabianca, AmpliPhi's last CEO, has left the company and the board of directors to pursue other interests.